Global Biotech API Market Analysis
Format : Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Jun, 2012| No. of Pages : 60
1. Analyst View
2. Research Methodology
3. Biotech Active Pharmaceutical Ingredients - An Introduction
4. Active Pharmaceutical Ingredient - Industry Performance
4.1 Current and Future Market Analysis to 2015
4.2 Branded and Generic APIs
4.3 Synthetic and Biotech APIs
5. Biotech Active Pharmaceutical Ingredients - Industry Performance
5.1 Current and Future Market Analysis to 2015
5.2 Biogeneric and Innovator Biotech APIs
5.3 Key Geographical Markets
6. Regulatory Environment
7. Competitive Landscape
7.1 Bayer Pharma AG
7.1.1 Business Overview
7.1.2 Strengths and Weaknesses
7.1.3 Recent Developments
7.2 Biocon Limited
7.2.1 Business Overview
7.2.2 Strengths and Weaknesses
7.2.3 Recent Developments
7.3 Boehringer Ingelheim
7.3.1 Business Overview
7.3.2 Strengths and Weaknesses
7.3.3 Recent Developments
7.4 Hospira
7.4.1 Business Overview
7.4.2 Strengths and Weaknesses
7.4.3 Recent Developments
7.5 Lonza
7.5.1 Business Overview
7.5.2 Strengths and Weaknesses
7.5.3 Recent Developments
7.6 Ranbaxy Laboratories
7.6.1 Business Overview
7.6.2 Strengths and Weaknesses
7.6.3 Recent Developments
7.7 Royal Dsm N.V.
7.7.1 Business Description
7.7.2 Strengths and Weaknesses
7.7.3 Recent Developments
7.8 Sigma-Aldrich
7.8.1 Business Overview
7.8.2 Strengths and Weaknesses
7.8.3 Recent Developments
7.9 Teva Active Pharmaceutical Ingredients
7.9.1 Business Overview
7.9.2 Strengths and Weaknesses
7.9.3 Recent Developments
7.10 Zhejiang Hisun Pharmaceutical Co. Ltd.
7.10.1 Business Overview
7.10.2 Strengths and Weaknesses
7.10.3 Recent Developments